title: Oxidised lipids present in ascitic fluid interfere with the regulation of the macrophages during acute pancreatitis, promoting an exacerbation of the inflammatory response.
abstract: BACKGROUND
  Pancreatitis-associated ascitic fluid (PAAF) plays a critical role in the pathogenesis of acute pancreatitis. Taking into consideration that damaged pancreas exudes high concentrations of lipolytic enzymes in the peritoneal cavity, large amounts of lipid metabolism derived products could occur in PAAF. In this study, we have examined the involvement of the lipid fraction of PAAF generated in the early stages of experimental acute pancreatitis.
  
  
  METHODS
  Pancreatitis was induced in rats by intraductal administration of 5% sodium taurocholate. After 3 h, PAAF was collected and its lipid fraction was obtained. Lipid composition and levels of lipid peroxidation were measured. Toxicity was evaluated by measuring the effects of the PAAF lipid fraction on cell viability of hepatic and macrophage cell lines. In vivo effects on the liver were also evaluated. Effects on the inflammatory response were determined by measuring the levels of nuclear factor kappa B (NF kappa B) activation, the effect on the inhibitory activity of 15-deoxy-PGJ(2) and the possible interference on PPAR gamma activation.
  
  
  RESULTS
  High concentrations of oxidised free fatty acids were detected in PAAF. Besides the direct cell toxicity, the PAAF-derived lipid extract interfered with the anti-inflammatory pathway mediated by PPAR gamma. Addition of this lipid extract to macrophage cell cultures had no direct effect on the activation of NF kappa B, but abolished the inhibitory activity of endogenous PPAR gamma agonists such as 15-deoxy-PGJ(2).
  
  
  CONCLUSIONS
  Oxidised free fatty acids present in PAAF interfere with the endogenous regulatory mechanism of the inflammatory response, thus promoting an exacerbation of macrophage activation in acute pancreatitis.
authors.affiliation: Department of Ischemia and Inflammation, Institut d'Investigacions Biomèdiques de Barcelona, Barcelona, Spain.
authors.forename: P T
authors.initials: PT
authors.lastname: Gutierrez
authors.forename: E
authors.initials: E
authors.lastname: Folch-Puy
authors.forename: O
authors.initials: O
authors.lastname: Bulbena
authors.forename: D
authors.initials: D
authors.lastname: Closa
mesh_terms: D000208:Acute Disease; D000818:Animals; D001202:Ascitic Fluid / Q000378:metabolism*; D002478:Cells, Cultured; D004247:DNA / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D050356:Lipid Metabolism / Q000502:physiology; D015227:Lipid Peroxidation / Q000502:physiology; D008055:Lipids / Q000032:analysis / Q000494:pharmacology; D008262:Macrophage Activation / Q000187:drug effects / Q000502:physiology*; D008264:Macrophages / Q000378:metabolism; D008297:Male; D016328:NF-kappa B / Q000187:drug effects / Q000378:metabolism; D047495:PPAR gamma / Q000037:antagonists & inhibitors / Q000187:drug effects / Q000378:metabolism; D010195:Pancreatitis / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D008055:Lipids; D016328:NF-kappa B; D047495:PPAR gamma; D004247:DNA